Pallas Capital Advisors LLC Purchases Shares of 26,435 Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Pallas Capital Advisors LLC bought a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 26,435 shares of the company’s stock, valued at approximately $2,237,000. Pallas Capital Advisors LLC owned 0.05% of Axsome Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Rhumbline Advisers grew its stake in shares of Axsome Therapeutics by 5.1% in the 2nd quarter. Rhumbline Advisers now owns 54,931 shares of the company’s stock worth $4,422,000 after buying an additional 2,674 shares during the last quarter. Arizona State Retirement System grew its position in Axsome Therapeutics by 2.1% during the 2nd quarter. Arizona State Retirement System now owns 8,630 shares of the company’s stock valued at $695,000 after purchasing an additional 177 shares during the last quarter. WINTON GROUP Ltd increased its stake in Axsome Therapeutics by 156.6% during the 2nd quarter. WINTON GROUP Ltd now owns 8,823 shares of the company’s stock valued at $710,000 after purchasing an additional 5,385 shares in the last quarter. Sofinnova Investments Inc. purchased a new position in Axsome Therapeutics in the second quarter worth about $24,971,000. Finally, XTX Topco Ltd lifted its stake in shares of Axsome Therapeutics by 177.9% in the second quarter. XTX Topco Ltd now owns 11,205 shares of the company’s stock worth $902,000 after buying an additional 7,173 shares in the last quarter. Institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Trading Up 11.5 %

Shares of NASDAQ:AXSM traded up $9.22 on Monday, hitting $89.27. 1,879,117 shares of the company’s stock were exchanged, compared to its average volume of 993,689. The business’s 50 day simple moving average is $92.17 and its two-hundred day simple moving average is $89.16. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.44 and a quick ratio of 2.37. The stock has a market capitalization of $4.33 billion, a price-to-earnings ratio of -13.67 and a beta of 1.04. Axsome Therapeutics, Inc. has a 12 month low of $64.11 and a 12 month high of $105.00.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($1.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.38) by $0.04. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. The company had revenue of $104.76 million during the quarter, compared to analysts’ expectations of $98.71 million. During the same period in the previous year, the company earned ($1.32) EPS. Analysts anticipate that Axsome Therapeutics, Inc. will post -4.6 EPS for the current fiscal year.

Analysts Set New Price Targets

AXSM has been the topic of several recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $121.00 price objective on shares of Axsome Therapeutics in a research report on Thursday, December 12th. Truist Financial raised their target price on Axsome Therapeutics from $150.00 to $180.00 and gave the stock a “buy” rating in a research report on Monday. Needham & Company LLC reissued a “buy” rating and set a $133.00 price objective on shares of Axsome Therapeutics in a research report on Monday. Robert W. Baird increased their target price on shares of Axsome Therapeutics from $112.00 to $116.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Finally, HC Wainwright reissued a “buy” rating on shares of Axsome Therapeutics in a report on Tuesday, December 31st. One investment analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $129.43.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.